Выбор редакции

Is There More Upside For Regeneron At $620?

Regeneron Pharmaceuticals’ stock (NASDAQ: REGN) has rallied 66% year-to-date to its current level of $622, significantly outperforming the S&P500, which is down 4%, due to a rapid increase in the number Covid-19 cases resulting in heightened fears of an imminent global economic downturn...
НОВОСТИ ПО ТЕМЕ